Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CCR5 | P51681 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857440 | 0.89 | CYP2D6 (0.61) | CYP2D6CCR5USP2GAAHTR2A | |
| SCHEMBL5858744 | 0.79 | DRD2 (0.68) | CYP2D6CCR5USP2ALDH1A1 | |
| SCHEMBL17538382 | 0.79 | CYP3A4 (0.58) | CYP2D6CCR5USP2GAAHTR2A | |
| SCHEMBL5858714 | 0.78 | CCR5 (0.83) | CYP2D6CCR5 | |
| SCHEMBL904850 | 0.78 | USP2 (0.60) | CYP2D6CCR5USP2GAAHTR2A | |
| SCHEMBL11201625 | 0.77 | USP2 (0.58) | CYP2D6USP2GAAHTR2AHTR7 | |
| SCHEMBL11100678 | 0.76 | ALDH1A1 (0.73) | CYP2D6USP2GAACYP3A4CYP2C19 | |
| SCHEMBL12153138 | 0.76 | USP2 (0.54) | CYP2D6CCR5USP2GAAHTR2A | |
| SCHEMBL5729319 | 0.76 | HTR2A (0.53) | CYP2D6CCR5USP2GAAHTR2A | |
| SCHEMBL5858640 | 0.74 | ALDH1A1 (0.61) | CYP2D6CCR5USP2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265870-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | CCR5, CCR2, CXCR4 | CYP2D6 521/4885CCR5 1/4885USP2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.